JPRN-UMIN000020267已完成未知
Quantitative assessment of the eldecalcitol effect on intestinal calcium absorption - Quantitative assessment of the eldecalcitol (ELD) effect on intestinal calcium absorption and comparison between ELD group, alfacalcidol (ALF) group, natural vitamin D group and non-treatment group with Osteoporotic women patients.(CalQ study)
Research secretariat (IDD, Inc.)0 个研究点目标入组 40 人开始时间: 2015年12月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Has a history of fragility fracture within a year. 2) Has complication or using medicines as follows. 1. Endocrine disease 2. Malignancy 3. Poor nutrition (undernourishment) 4. Gout 5. Lactose intolerance 3) Has gastric resection or gastric bypass surgery. 4) Has taken bisphosphonate medicine (included investigational new drug) within 6 months before starting of dosing. 5) Has taken RANKL antibody in the past at a time. 6) Has taken following medications effected to born metabolism within 4 weeks before dosing. 1. Selective estrogen receptor modulators formulation 2. Calcitonin preparation 3. Vitamin K2 preparation 4. Ipriflavone preparation 5. Sex hormone preparation (without tablet or cream vaginal agents) 6. Active vitamin D3 preparation 7. Native vitamin D preparation 8. Ca preparation 9. Other drug or supplement those effect to born metabolism. 7) Has taken following drugs effected to Ca absorption and elimination within 4 weeks before dosing. 1. Steroid preparation (excluded external preparation and local injection with inhalation, nasal preparation) 2. Other drugs or supplements effected to Ca absorption and elimination. 8) Has taken parathyroid hormone preparation in the past at a time. 9) Has taken anti- sclerostin antibody or cathepsin K-inhibitor in the past at a time. 10) Has taken other investigational new drug (included placebo) within 16 weeks before dosing. 11) Has caught extreme rays by sunbath at a resort within a month before dosing. 12) Serum Ca at the registration is more than 10.4 mg/dL or less than 8.0 mg/dL. 13) Urine Ca is over than 0.4 mg/dL GF. 14) Has currently or a history of urinary tract stone. 15) eGFR at registration is less than 30mL/min/1.73m2. 16) Has advanced liver disease like cirrhosis or advanced heart disease like serious heart failure. 17) Has hypersensitivity to ELD, ALF or other vitamin D preparation. 18) Other people who are judged by the investigator or the subinvestigator as inappropriate to participate in this study.
研究者
相似试验
招募中
不适用
Examination for the effect of eldecalcitol on muscle strength in primary osteoporotic patientsOsteoporosisJPRN-UMIN000008464TT East Tohoku Hospital160
已完成
不适用
The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosisJPRN-UMIN000007070Department of Hepatology, Osaka City University Graduate School of Medicine50
尚未招募
不适用
The effect of eldecalcitol on bone mineral density and bone markers for osteoporotic patients with type 2 diabetes.-Open label multicenter studyosteoporosisJPRN-UMIN000008417Shimane University Faculty of Medicine30
尚未招募
不适用
The comparison of Eldecalcitol and Alfacalcidol on early osteoporosis caused by Anastrozole / Letrozole for post-operative breast cancer.JPRN-UMIN000009183Kansai Medical University120
已完成
不适用
The additive effect of Eldecalcitol for glucocorticoid induced osteoporosis responding poorly to Alendronate.glucocorticoid induced osteoporosisJPRN-UMIN000009586Department of Rheumatic Disease, Shinko Hospital80